Drugs / TRC150094
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03254446 | Mar 2018 → Apr 2022 | diabetes mellitus, hyperlipidemia, hypertensive disorder | Torrent Pharmaceuticals Limited | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01408667 Comparator | Nov 2011 → Mar 2012 | metabolic syndrome X | Torrent Pharmaceuticals Limited | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRC150094 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03254446 ↗ |
| Known as | Omzotirome | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297445 ↗ |
| Modality | Other / unclassified | “a thyroid hormone mimetic” PMID 24586256 ↗ Feb 2014 |
| Route | Oral | “TRC150094 45 mg Tablet to be administered orally once a day for 50 weeks” NCT03254446 ↗ |